20 April 2022 | Wednesday | News
Image Source : Public Domain
The investment reinforces Excelra's push into the Health Economics and Outcomes Research (HEOR) and Real-World Evidence (RWE) analytics area. This deal is a testimony to Excelra's commitment to drug discovery and commercialization by combining deep scientific domain expertize with cutting-edge technology and analytics solutions.
Anlitiks, headquartered in Boston, is a HEOR and RWE company, founded by Kannan Rajagopalan, a technology entrepreneur. According to Kannan, Anlitiks' mission is to help Life Sciences organizations translate real-world data rapidly into value evidence, using a unique data + platform + service approach. The engine driving the business is Anlitiks' RapidAnalyzer™, a flexible, data-agnostic platform that captures the entire lifecycle of HEOR/RWE from hypothesis, data integration, analysis, visualization to a research report. RapidAnalyzer™ changes the competitive landscape by drastically reducing the time taken to gain valuable insights on large-scale data from months to just a matter of weeks.
As President and Chief Scientific Officer at Anlitiks, Dr. Krithika (Kitty) Rajagopalan, an industry veteran and well-published HEOR, RWE, Pricing, and Market Access executive, helps provide leadership and direction in defining reimbursable strategies for biopharmaceutical organizations.
Anandbir Brar, Chief Executive Officer at Excelra, mentioned, "Anlitiks has a unique platform + consulting business model, combining highly skilled and experienced HEOR experts, and an integrated platform - RapidAnalyzer™ that helps execute large volumes of analytical workflows. Our combined strength empowers Life Science organizations with accelerated yet informed decision-making."
Data and Digital transformation have become a strategic imperative for the Life Sciences industry to break down silos between multi-omics, clinical trials, and real-world data. The partnership with Anlitiks augments Excelra's vision to use domain-led data science to empower innovation from discovery to market.
Kannan Rajagopalan stated, "Our vision is to be a technology-enabled disruptive force in generating rapid actionable insights for the Life Science industry using real-world data. Excelra's focus areas dovetail perfectly with our growth strategy, making it the beginning of an exciting journey."